Epirubicin improves HER2-positive breast cancer survival

Epirubicin improves HER2-positive breast cancer survival


The HER2 receptor dimer transmembrane signal transduction pathway

In the recent decades, women’s health has taken center stage. No longer hidden in obscurity, breast cancer emerged as a growing concern for women all over the world. The disease does not just strike women, it affects children and men as well, albeit indirectly. The role of the woman as a mom and earning partner in a family unit can be severely undermined by the disease. The growing cost of cancer treatment, poor prognosis and long term uncertainties brought on by breast cancer can shake even the most stable of families. For women with HER2-positive breast cancer, the battle is even harder.  This is because it is more aggressive than the HER2-negative type. In about 1 of every 5 breast cancers, the cancer cells make an excess of human epidermal growth factor receptor 2 (HER2) through a gene mutation. What’s more, this is also less responsive to cancer treatment.

Despite all these harrowing news, there’s a light at the end of the tunnel. There are available treatments that specifically target HER2 and have so far been found to be effective. But this effectiveness comes with a price: high costs and debilitating side effects, particularly, an increased susceptibility to opportunistic infections. That is why LGM Pharma works diligently with pharmaceutical firms who have dedicated their resources and manpower to developing novel ways to combat this particular form of cancer.

Women who produce excessive HER2 can particularly benefit from an anthracycline-based chemotherapy. Anthracyclines are anticancer drugs derived from a certain strain of bacteria and is considered effective against a wider range of cancer than any other anticancer agents in the market today. A combination of data from eight randomized clinical trials published by the Journal of Cancer Institute in January 2008 supports the use of Epirubicin CAS# 56420-45-2 in women with HER2-positive breast cancer for cancer extension of cancer survival compared with non-anthracycline-based chemotherapy. Although the results show promising clinical outcomes, the medical community agrees that toxicity data and dosages need to be further investigated in order to provide patients with better clinical treatment results.

LGM Pharma recognizes the importance of women’s health in the society and as such, have extended their cooperation with research firms who are involved in addressing the health issues that plague women today. By providing a steady stream of Epirubicin CAS# 56420-45-2 to these firms, the company has allowed their research endeavors to prosper without worrying about the integrity of their results because this product pass quality regulatory tests.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service